Loading company…
Merus develops bispecific and multispecific antibody therapeutics for cancer and other diseases.
Founded in 2003 in the Netherlands, Merus is a biotechnology company developing antibody therapeutics through its Multiclonics platform. Its candidates target cancer, infectious diseases, and inflammatory conditions; clinical candidates include MCLA-128, MCLA-129, MCLA-158, MCLA-145, and ONO-4685. Merus listed on Nasdaq in May 2016 under ticker MRUS and raised USD 150 million in a private placement in August 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in